WO2010007803A1 - ナノ粒子標識薬、及び該ナノ粒子標識薬を用いたシステム - Google Patents
ナノ粒子標識薬、及び該ナノ粒子標識薬を用いたシステム Download PDFInfo
- Publication number
- WO2010007803A1 WO2010007803A1 PCT/JP2009/053002 JP2009053002W WO2010007803A1 WO 2010007803 A1 WO2010007803 A1 WO 2010007803A1 JP 2009053002 W JP2009053002 W JP 2009053002W WO 2010007803 A1 WO2010007803 A1 WO 2010007803A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modality
- nanoparticle labeling
- drug according
- substance
- core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
- A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
- A61B6/5247—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from an ionising-radiation diagnostic technique and a non-ionising radiation diagnostic technique, e.g. X-ray and ultrasound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0404—X-ray contrast preparations containing barium sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/508—Clinical applications for non-human patients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
- Y10T428/2993—Silicic or refractory material containing [e.g., tungsten oxide, glass, cement, etc.]
Definitions
- the present invention relates to a nanoparticle labeling drug and a system for obtaining a high resolution in vivo image using the nanoparticle labeling drug.
- optical imaging does not expose patients to ionizing radiation, it is always well accepted as a diagnostic modality.
- Optical imaging is based on the detection of differences in absorption, scattering and / or fluorescence between normal and tumor tissue.
- the fluorescent molecule ie, optical imaging agent
- detectable light ie, light of a different wavelength
- Optical imaging agents increase the target / background ratio by orders of magnitude, increasing the visibility and discrimination of the target area.
- Optical imaging agents can be designed to emit detectable light only when a special event is present (only in the presence of a given enzyme). Optical imaging is highly promising for detecting functional or metabolic changes such as overproduction of specific proteins or enzymes in the body. For most diseases this is useful because it induces the desired functional or metabolic changes in the body before anatomical changes occur. The ability to detect these metabolic changes allows for early detection, diagnosis and treatment of the disease, improving patient remission and / or healing opportunities.
- magnetic resonance imaging capable of rendering a tissue image that cannot be depicted with X-rays can be used at the same time, physical properties of a substance different from X-rays can be measured, which is useful, for example, in improving the position and extent of a lesion. . It has the advantage of creating a new diagnostic area called diagnosis by multi-modality imaging.
- a nanoparticle labeling drug comprising core / shell type semiconductor nanoparticles having an average shell thickness of 0.1 nm or more and 10.0 nm or less and an X-ray sensitive material.
- the X-ray sensitive material is scandium (Sc), titanium (Ti), vanadium (V), chromium (Cr), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn) , Gallium (Ga), selenium (Se), bromine (Br), rubidium (Rb), strontium (Sr), yttrium (Y), zirconium (Zr), niobium (Nb), molybdenum (Mo), ruthenium (Ru) , Rhodium (Rh), palladium (Pd), silver (Ag), cadmium (Cd), iridium (Ir), tellurium (Te), iodine (I), cesium (Cs), barium (Ba), lanthanum (La) , Cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (
- nanoparticle labeling drug according to 1 or 2 further comprising a substance for binding the core / shell type semiconductor nanoparticles and the X-ray sensitive material.
- nanoparticle labeling drug according to any one of 1 to 4, wherein SiO 2 is contained in a shell of the core / shell type semiconductor nanoparticles.
- nanoparticle labeling drug according to any one of 1 to 5, further comprising magnetic particles.
- nanoparticle labeling agent according to 8 wherein the metal oxide is selected from the group consisting of cobalt oxide, nickel oxide, manganese oxide and iron oxide.
- the paramagnetic substance contains a chelated gadolinium complex as a base and contains one or more paramagnetic ions in the chelate.
- the paramagnetic ions are manganese (Mn), praseodymium (Pr), neodymium (Nd), samarium (Sm), europium (Eu), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), 12.
- a second modality capable of detecting the absorption of an X-ray sensitive material in a particle labeling drug is provided, and the first modality and the second modality can be used simultaneously. system.
- the first modality capable of detecting the fluorescence of the core / shell type semiconductor nanoparticles in the nanoparticle labeling agent according to any one of 6 to 12, and the nanoparticles according to any one of 6 to 12 above.
- the second modality capable of detecting the absorption of the X-ray sensitive material in the labeling drug, and the third modality capable of detecting the magnetic property of the magnetic particle in the nanoparticle labeling drug according to any one of the above 6 to 12.
- a system for obtaining a high-resolution in vivo image wherein the first modality, the second modality, and the third modality can be used simultaneously.
- nanoparticle labeling drug that can be used simultaneously in X-ray imaging and optical imaging, and X-ray imaging, optical imaging, and magnetic resonance imaging, respectively.
- nanostructure crystals exhibit specific optical characteristics in semiconductor ultrafine particles such as Si and Ge, and II-VI group semiconductors such as porous silicon.
- the nanostructure crystal refers to a crystal grain having a particle size on the order of nanometers of about 1 to 100 nm, and is generally abbreviated as “nanoparticle” or “nanocrystal”.
- the nanostructure crystal when the nanostructure crystal is compared with the case of having the nanostructure crystal as described above, the nanostructure crystal exhibits good light absorption characteristics and light emission characteristics. become. This is presumably because a II-VI group semiconductor having a nanostructure crystal exhibits a quantum size effect and thus has a larger band gap than a bulk crystal structure. That is, in the II-VI group semiconductors having nanostructure crystals, it is considered that the energy gap of the semiconductor nanoparticles increases as the particle size decreases due to the manifestation of the quantum size effect.
- the semiconductor nanoparticles have a core / shell structure.
- the semiconductor nanoparticles are semiconductor nanoparticles having a core / shell structure composed of core particles made of semiconductor particles and a shell covering the core particles, and the chemical composition of the core particles and the shell is different. It is preferable that Thus, the band gap of the shell is preferably higher than that of the core.
- the shell is necessary for stabilizing the surface defects of the core particles and improving the brightness, and is also important for forming a surface on which the surface modifier is easily adsorbed and bonded. This is also an important configuration for improving the accuracy of detection sensitivity for the effect of the present invention.
- a particularly preferable semiconductor material is Si.
- the average particle size of the core according to the present invention is preferably 0.5 to 15 nm.
- the average particle diameter of the semiconductor nanoparticles must originally be determined in three dimensions, but it is difficult because it is too fine, and in reality it must be evaluated with a two-dimensional image. Therefore, a transmission electron microscope (TEM) ) Is preferably obtained by averaging a large number of images taken by changing the shooting scene of the electron micrograph. Therefore, the number of particles photographed with a TEM is preferably 100 or more.
- TEM transmission electron microscope
- the semiconductor nanoparticles according to the present invention emit fluorescence in the wavelength region of the infrared region, that is, emit infrared light.
- Various semiconductor materials can be used as the semiconductor material used for the shell. Specific examples include, for example, ZnO, ZnS, ZnSe, ZnTe, CdO, CdS, CdSe, CdTe, MgS, MgSe, GaS, GaN, GaP, GaAs, GaSb, InAs, InN, InP, InSb, AlAs, AlN, AlP. , AlSb, or a mixture thereof.
- preferred semiconductor materials are SiO 2 , GeO 2 , and ZnS, with SiO 2 being most preferred.
- the shell according to the present invention may not completely cover the entire surface of the core particle as long as the core particle is not partially exposed to cause a harmful effect.
- the average shell thickness is 0.1 nm or more and 10.0 nm or less.
- the average particle size of the core / shell type semiconductor nanoparticles according to the present invention is 1 to 10 nm.
- nano-sized particles having a particle diameter smaller than the wavelength of electrons (about 10 nm) have a large size finite effect on electron motion as a quantum size effect. Therefore, it is known that it exhibits unique physical properties different from those of bulk bodies.
- quantum dots semiconductor nanoparticles that exhibit a quantum confinement effect with a nanometer-sized semiconductor material are also referred to as “quantum dots”.
- quantum dots Such a quantum dot is a small lump within about 10 and several nanometers in which several hundred to several thousand semiconductor atoms are gathered, but when absorbing energy from an excitation source and reaching an energy excited state, the energy of the quantum dot Releases energy corresponding to the band gap. Therefore, by adjusting the size or material composition of the quantum dots, the energy band gap can be adjusted and energy in various levels of wavelength bands can be used.
- quantum dots that is, semiconductor nanoparticles, have a feature that the emission wavelength can be controlled by changing the particle size with the same composition.
- the core / shell type semiconductor nanoparticles according to the present invention can be adjusted so as to emit fluorescence in the range of 350 to 1100 nm.
- the influence of light emission of living cells themselves is eliminated and the SN ratio is increased.
- light emission with a wavelength in the near infrared region is also preferably used.
- liquid phase method examples include a precipitation method, a coprecipitation method, a sol-gel method, a uniform precipitation method, and a reduction method.
- reverse micelle method, supercritical hydrothermal synthesis method and the like are also excellent methods for producing nanoparticles (for example, JP 2002-322468, JP 2005-239775, JP 10-310770 A). (See JP 2000-104058 A).
- the semiconductor precursor according to the present invention is a compound containing an element used as the semiconductor material, for example, when the semiconductor is silicon (Si), and the like SiCl 4 as semiconductor precursor.
- examples of the semiconductor precursor include InCl 3 , P (SiMe 3 ) 3 , ZnMe 2 , CdMe 2 , GeCl 4 , and tributylphosphine selenium.
- the reaction temperature of the reaction precursor is not particularly limited as long as it is not lower than the boiling point of the semiconductor precursor and not higher than the boiling point of the solvent, but is preferably in the range of 70 to 110 ° C.
- reducing agent for reducing the semiconductor precursor various conventionally known reducing agents can be selected and used according to the reaction conditions.
- lithium aluminum hydride (LiAlH 4 ), sodium borohydride (NaBH 4 ), sodium bis (2-methoxyethoxy) aluminum hydride, trihydride (sec- Reducing agents such as lithium (butyl) boron (LiBH (sec-C 4 H 9 ) 3 ), potassium tri (sec-butyl) borohydride, and lithium triethylborohydride are preferred.
- lithium aluminum hydride (LiAlH 4 ) is preferable because of its reducing power.
- solvents can be used as the solvent for dispersing the semiconductor precursor.
- Alcohols such as ethyl alcohol, sec-butyl alcohol and t-butyl alcohol, and hydrocarbon solvents such as toluene, decane and hexane are used. It is preferable to use it.
- a hydrophobic solvent such as toluene is particularly preferable as the dispersion solvent.
- ⁇ Surfactant> various conventionally known surfactants can be used, and anionic, nonionic, cationic, and amphoteric surfactants are included. Of these, tetrabutylammonium chloride, bromide or hexafluorophosphate, tetraoctylammonium bromide (TOAB), or tributylhexadecylphosphonium bromide, which are quaternary ammonium salts, are preferred. Tetraoctyl ammonium bromide is particularly preferable.
- the reaction by the liquid phase method varies greatly depending on the state of the compound containing the solvent in the liquid.
- special care must be taken.
- the size and state of the reverse micelle serving as a reaction field vary depending on the concentration and type of the surfactant, so that the conditions under which nanoparticles are formed are limited. Therefore, a suitable surfactant needs to be combined with a solvent.
- the opposing raw material semiconductor is evaporated by the first high temperature plasma generated between the electrodes, and in the second high temperature plasma generated by electrodeless discharge in a reduced pressure atmosphere.
- a method for separating and removing nanoparticles from an anode made of a raw material semiconductor by electrochemical etching for example, see JP-A-2003-515459)
- laser ablation method for example, see JP-A No. 2004-356163
- high-speed sputtering method for example, see JP-A No. 2004-296781
- a method of synthesizing a powder containing particles by reacting a raw material gas in a gas phase in a low pressure state is also preferably used.
- the method for producing core / shell type semiconductor nanoparticles according to the present invention includes a step of performing a post-treatment of any of plasma, heat, radiation, and ultrasonic treatment after the formation of the semiconductor nanoparticles, particularly after the formation of the shell. Is also preferable.
- microwave plasma treatment in consideration of the particle composition, crystallinity, and surface properties, a suitable one such as low temperature / high temperature plasma, microwave plasma, atmospheric pressure plasma is selected, but microwave plasma is preferable.
- any one of air, vacuum, and inert gas region is selected and heated, but the applied temperature region differs depending on the structure of the phosphor particles. If the temperature is too high, the core and the shell may be distorted or peeled off. The effect is poor at low temperatures, and a temperature of 100 ° C. or higher and 300 ° C. or lower is preferably used.
- Radiation treatment uses X-rays, ⁇ -rays, and neutrons that require high energy, or vacuum ultraviolet rays (VUV), ultraviolet rays, or short pulse lasers that have low energy.
- VUV vacuum ultraviolet rays
- the processing time varies depending on the type of radiation. Since X-rays and the like have a high transmission power, a relatively short time is often required for any composition, and ultraviolet rays require a relatively long time of irradiation.
- the X-ray sensitive material is scandium (Sc), titanium (Ti), vanadium (V), chromium (Cr), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn), gallium (Ga), selenium (Se), bromine (Br), rubidium (Rb), strontium (Sr), yttrium (Y), zirconium (Zr), niobium (Nb), molybdenum (Mo), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), cadmium (Cd), iridium (Ir), tellurium (Te), iodine (I), cesium (Cs), barium (Ba), lanthanum (La), Cerium (Ce), Praseodymium (Pr), Neodymium (Nd), Promethium (Pm), Samarium (Sm), Euro
- the substance for binding the core / shell type semiconductor nanoparticles and the X-ray sensitive material together refers to a compound that can be bonded to either composition, although it differs depending on the composition of the particles.
- X-ray sensitive materials are metals, and metal oxides can be mentioned considering the composition of core / shell type semiconductor nanoparticles.
- a preferred example is silica.
- the first modality can be used without particular limitation as long as it is an apparatus capable of detecting fluorescence.
- a confocal microscope, a two-photon microscope, a microscope for small animals such as Olympus OV-100 can be used.
- X-CT capable of measuring X-ray absorption
- Micro X-CT is preferred for small animals.
- micro MRI is suitable for small animals, in which magnetic resonance imaging capable of measuring magnetism can be used.
- the magnetic particles are superparamagnetic substances, paramagnetic substances or ferromagnetic substances, and specifically metal oxides.
- the metal oxide is preferably selected from the group consisting of cobalt oxide, nickel oxide, manganese oxide and iron oxide (for example, Fe 3 O 4 , ⁇ -Fe 2 O 3 ).
- a superparamagnetic substance is a substance having a stronger magnetism than a ferromagnetic substance, and examples thereof include iron oxide used as a superparamagnetic iron oxide preparation (SPIO).
- a paramagnetic substance is a substance that does not have magnetization when there is no external magnetic field, and refers to magnetism that weakly magnetizes in that direction when a magnetic field is applied. Examples include crystals containing elements with incomplete electron shells (Fe, Mn, etc.), pyrite, siderite, pyroxene.
- a ferromagnetic substance is a substance that refers to the magnetism of a substance that has adjacent spins aligned in the same direction and has a large magnetic moment as a whole. Therefore, the material can have spontaneous magnetization without an external magnetic field. There are few simple substances that exhibit ferromagnetism at room temperature, such as iron, cobalt, nickel, and gadolinium.
- paramagnetic substances include those containing one or more of a chelated gadolinium complex and a paramagnetic ion chelate.
- the paramagnetic ions manganese (Mn), praseodymium (Pr), neodymium (Nd), samarium (Sm), europium (Eu), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium Examples include one or more of (Er), thulium (Tm), ytterbium (Yb), and lutetium (Lu).
- Example 1 Production of nanoparticle labeling drug containing core / shell type semiconductor nanoparticles and X-ray sensitive particles >> (Preparation of X-ray sensitive particles) 1.71 g of barium hydroxide and 0.98 g of sulfuric acid were dissolved in 1000 g of ion-exchanged water, respectively, to obtain a 0.01 mol / L barium hydroxide solution and a 0.01 mol / L sulfuric acid solution. Next, a 2 L flask was charged with a sulfuric acid solution, stirred at 200 rpm with a Teflon (registered trademark) paddle, heated to 100 ° C., and then charged with a barium hydroxide solution heated to 100 ° C. in 30 seconds.
- Teflon registered trademark
- the fluorescent Si quantum dot was manufactured as follows.
- toluene and heptene in the solution were removed by a rotary evaporator.
- 100 ml of hexane was added thereto, 200 ml of N-methylformamide was further added, and the mixture was transferred to a separatory funnel and stirred to separate the unreacted reducing agent and surfactant transferred to N-methylformamide. Went.
- the operation after addition of 200 ml of N-methylformamide was further performed twice to obtain core / shell type semiconductor nanoparticles composed of Si capped with 1-heptene in hexane.
- the obtained nanoparticles had a particle diameter of 2 nm and a shell thickness of 1 nm.
- a buffer salt is added to the above solution, and a surface modifying compound having a polyethylene glycol chain with a molecular weight of 2000 having an amino group introduced at one end and a carboxyl group introduced at one end is selected and added together with the catalyst carbodiimide for 24 hours at room temperature. And stirred. In this way, the target biomarker was obtained.
- Example 2 Preparation of nanoparticle labeling drug containing core / shell type semiconductor nanoparticles, X-ray sensitive particles and magnetic particles >> (Preparation of magnetic particles) 1.622 g of iron (III) chloride (FeCl 3 ) and 5.560 g of iron (II) sulfate (FeSO 4 .7H 2 O) were dissolved in 200 ml of deionized water deoxygenated overnight with nitrogen bubbles. . The iron (III) ion concentration ([Fe 3+ ]) was 0.05 mol / L, and the iron (II) ion concentration ([Fe 2+ ]) was 0.10 mol / L.
- nanoparticles containing magnetic particles, X-ray sensitive particles and fluorescent Si quantum dots 15 mg of the magnetic particles prepared in the above method, 15 mg of the X-ray sensitive particles prepared in the above method, and 15 mg of the Si quantum dots prepared in the above method are sonicated into 100 ml of 2-propanol by sonication. Dispersed for longer than minutes. As a result, these two types of particles were sufficiently dispersed in this solution.
- nanoparticles were obtained using the same method as in Example 1. The obtained nanoparticles were 30 nm.
- GdVO 4 Preparation of nanoparticles containing Eu particles and X-ray sensitive particles
- 15 mg of GdVO 4 Eu particles prepared in the above method and 15 mg of X-ray sensitive particles prepared in the above method were dispersed in 100 ml of 2-propanol by sonication for longer than 30 minutes. As a result, these two types of particles were sufficiently dispersed in this solution. The following were used to obtain nanoparticles using the same method as in Example 1. The obtained nanoparticles were 35 nm.
- the biomarker obtained as described above is injected into the blood vessel by injection from the vein of the mouse, and an image of the liver portion where the biomarker is collected using GE Micro X-CT and Micro MRI, Olympus OV-1000. Comparison of X-ray image contrast and MRI contrast and relative emission intensity were measured.
- the relative light emission intensity is the light emission intensity after 2 hours irradiation when the light emission intensity when the excitation light for observation of optical imaging is first irradiated is 100.
- X-ray image contrast A Very clear O: Normal as an image and not prominent ⁇ : The image has a feeling of blur and roughness.
- Example 2 shows either MRI contrast or relative light emission intensity. Is also an excellent evaluation result.
Abstract
Description
"ナノ工学・超臨界で量子ドットをつくる"阿尻雅文、第15回バイオイメージング学会学術集会(公開シンポジウム)2006年10月
近年、SiやGe等に代表される半導体超微粒子、ポーラスシリコン等のII-VI族半導体において、そのナノ構造結晶が特異的な光学的特性を示すことが注目されている。ここで、ナノ構造結晶とは1~100nm程度のナノメートルオーダーの粒径の結晶粒のことを言い、一般的に「ナノ粒子」、「ナノクリスタル」等の略称で呼ばれている。
コア粒子に用いられる半導体材料としては、種々の半導体材料を用いることができる。具体例としては、例えば、MgS、MgSe、MgTe、CaS、CaSe、CaTe、SrS、SrSe、SrTe、BaS、BaTe、ZnS、ZnSe、ZnTe、CdS、CdSe、CdTe、GaAs、GaP、GaSb、InGaAs、InP、InN、InSb、InAs、AlAs、AlP、AlSb、AlS、PbS、PbSe、Ge、Si、またはこれらの混合物等が挙げられる。本発明において、特に好ましい半導体材料は、Siである。
シェルに用いられる半導体材料としては、種々の半導体材料を用いることができる。具体例としては、例えば、ZnO、ZnS、ZnSe、ZnTe、CdO、CdS、CdSe、CdTe、MgS、MgSe、GaS、GaN、GaP、GaAs、GaSb、InAs、InN、InP、InSb、AlAs、AlN、AlP、AlSb、またはこれらの混合物等が挙げられる。
本発明に係るコア/シェル型半導体ナノ粒子の平均粒径は、1~10nmである。
本発明に係るコア/シェル型半導体ナノ粒子の製造方法としては、従来公知の液相法または気相法による製造方法を用いることができる。
半導体前駆体を還元する還元剤としては、従来周知の種々の還元剤を反応条件に応じて選択し用いることができる。本発明においては、還元力の強さの観点から、水素化アルミニウムリチウム(LiAlH4)、水素化ホウ素ナトリウム(NaBH4)、水素化ビス(2-メトキシエトキシ)アルミニウムナトリウム、水素化トリ(sec-ブチル)ホウ素リチウム(LiBH(sec-C4H9)3)及び水素化トリ(sec-ブチル)ホウ素カリウム、水素化トリエチルホウ素リチウムなどの還元剤が好ましい。特に、還元力の強さから水素化アルミニウムリチウム(LiAlH4)が好ましい。
半導体前駆体の分散用溶媒としては、従来周知の種々の溶媒を使用できるが、エチルアルコール、sec-ブチルアルコール、t-ブチルアルコール等のアルコール類、トルエン、デカン、ヘキサンなどの炭化水素類溶媒を使用することが好ましい。本発明においては、特にトルエン等の疎水性の溶媒が分散用溶媒として好ましい。
界面活性剤としては、従来周知の種々の界面活性剤を使用でき、陰イオン、非イオン、陽イオン、両性界面活性剤が含まれる。中でも、第四級アンモニウム塩系である、テトラブチルアンモニウムクロリド、ブロミドまたはヘキサフルオロホスフェート、テトラオクチルアンモニウムブロミド(TOAB)、またはトリブチルヘキサデシルホスホニウムブロミドが好ましい。特に、テトラオクチルアンモニウムブロミドが好ましい。
本発明に係るコア/シェル型半導体ナノ粒子の製造方法においては、半導体ナノ粒子形成後、特にシェル形成後にプラズマ、熱、放射線、または超音波による処理のいずれかの後処理を行う工程を含む態様も好ましい。
本発明において、X線感応材料がスカンジウム(Sc)、チタン(Ti)、バナジウム(V)、クロム(Cr)、鉄(Fe)、コバルト(Co)、ニッケル(Ni)、銅(Cu)、亜鉛(Zn)、ガリウム(Ga)、セレン(Se)、臭素(Br)、ルビジウム(Rb)、ストロンチウム(Sr)、イットリウム(Y)、ジルコニウム(Zr)、ニオブ(Nb)、モリブデン(Mo)、ルテニウム(Ru)、ロジウム(Rh)、パラジウム(Pd)、銀(Ag)、カドミウム(Cd)、イリジウム(Ir)、テルル(Te)、ヨウ素(I)、セシウム(Cs)、バリウム(Ba)、ランタン(La)、セリウム(Ce)、プラセオジム(Pr)、ネオジム(Nd)、プロメチウム(Pm)、サマリウム(Sm)、ユウロピウム(Eu)、ガドリニウム(Gd)、テルビウム(Tb)、ジスプロシウム(Dy)、ホルミウム(Ho)、エルビウム(Er)、ツリウム(Tm)、イッテルビウム(Yb)、ルテチウム(Lu)、ハフニウム(Hf)、タンタル(Ta)、タングステン(W)、オスミウム(Os)、イリジウム(Ir)、白金(Pt)、金(Au)から選択された少なくとも1種を含むことが好ましい。
《コア/シェル型半導体ナノ粒子とX線感応粒子とを含むナノ粒子標識薬の作製》
(X線感応粒子の調製)
水酸化バリウム1.71gと硫酸0.98gをイオン交換水1000gにそれぞれ溶解し、0.01mol/Lの水酸化バリウム溶液と0.01mol/Lの硫酸溶液とした。次に、2Lフラスコに硫酸溶液を仕込み、テフロン(登録商標)製パドルにて200rpmで攪拌、100℃まで加熱後、100℃に加熱した水酸化バリウム溶液を30秒で投入した。その後、3分間攪拌を続けた後、反応を終了した。次いで、常温まで冷却し、5Cの濾紙で濾過してイオン交換水を用いて水洗後、105℃で3時間乾燥して硫酸バリウムの粉末2.1gを得た。得られたナノ粒子の粒子径は11nmであった。
蛍光性Si量子ドットは、以下のように製造した。
上記方法において調製された15mgのX線感応粒子と、上記方法において調製されたSi量子ドット15mgとを100mlの2-プロパノール中へ超音波処理によって30分間より長時間分散させた。
アクリル酸重合体(和光純薬工業製、平均分子量約5,000)をそれぞれクロロホルム中に溶解し、クロロホルム溶液を調製した。クロロホルム中に上記ナノ粒子を分散した液を200μl、前記重合体クロロホルム溶液800μlを水10mlに投入し、超音波照射と攪拌を行った。クロロホルムを70℃2時間で除去することでポリマーコーティングされたナノ粒子水溶液を得た。
上記溶液にバッファ塩を添加し、更に一端にアミノ基が導入され、且つ片端にカルボキシル基が導入された分子量2000のポリエチレングリコール鎖を持つ表面修飾化合物を選択し、触媒のカルボジイミドとともに加え24時間室温で攪拌した。こうして目的の生体標識剤を得た。得られた生体標識剤の作製に用いた各原材料成分と目的物を選択的に分離するサイズ選択性カラムと化学的吸着するカラムを用いて、連続もしくは別々に全てのカラムでのGPC、HPLC処理を行い、生体標識剤を分取した。
《コア/シェル型半導体ナノ粒子とX線感応粒子と磁性粒子とを含むナノ粒子標識薬の作製》
(磁性粒子の調製)
1.622gの塩化鉄(III)(FeCl3)と5.560gの硫酸鉄(II)(FeSO4・7H2O)を、一晩窒素の泡で脱酸素した200mlの脱イオン水中に溶解した。この鉄(III)イオンの濃度([Fe3+])は0.05mol/Lで、この鉄(II)イオンの濃度([Fe2+])は0.10mol/Lであった。1.0gのポリグリコール-4000をこの混合物中に加え、超音波処理によって30分間分散させた。この混合物を60℃の温度で急速に攪拌した。次いで、10mlの28%アンモニアをこの混合物に急速に加えた。この混合物を常に窒素雰囲気下で30分間急速に攪拌した。この超常磁性粒子を、マグネティックコンセントレーターを用いて分離し、脱イオン水とアルコールで数回洗浄した。これらの粒子を60℃の温度で一晩真空乾燥した。濃い茶色のナノメートルサイズにされた磁性粒子を、すりつぶした後に得た。得られた磁性粒子の粒子径は10nmであった。
実施例1と同様の方法で調製した。
実施例1と同様の方法で調製した。
上記方法において調整された15mgの磁性粒子と上記方法において調製された15mgのX線感応粒子と、上記方法において調製されたSi量子ドット15mgとを、100mlの2-プロパノール中へ超音波処理によって30分間より長時間分散させた。その結果、これら2種類の粒子はこの溶液中へ十分に分散した。以下、実施例1と同様の方法を用いてナノ粒子を得た。得られたナノ粒子は30nmであった。
実施例1と同様の方法で調製した。
《GdVO4:Eu粒子とX線感応粒子とを含むナノ粒子標識薬の作製》
(GdVO4:Eu粒子の調製)
超臨界水熱合成方法によりGdVO4:Eu粒子を調製した。得られた粒径は30nmであった。
実施例1と同様の方法で行った。
上記方法において調製された15mgのGdVO4:Eu粒子と上記方法において調製された15mgのX線感応粒子を、100mlの2-プロパノール中へ超音波処理によって30分間より長時間分散させた。その結果、これら2種類の粒子はこの溶液中へ十分に分散した。以下は実施例1と同様の方法を用いてナノ粒子を得た。得られたナノ粒子は35nmであった。
実施例1と同様の方法で調製した。
以上によって得た生体標識剤をマウス静脈部より注射により血管に注入し、生体標識剤が集まった肝臓部での画像をGE製マイクロX-CTとマイクロMRI、オリンパス社製OV-1000を用いてX線画像コントラスト、MRIコントラストの比較と相対発光強度を測定した。相対発光強度とは、光学イメージングの観察用の励起光を最初に照射したときの発光強度を100としたときの2時間照射後の発光強度である。
◎:非常に鮮明である
○:画像として普通で際立ちは無い
△:画像にぼけとざらつき感がある。
◎:非常に良好な画像で診断可
○:普通の一般画像
△:鮮明性に欠ける。
Claims (16)
- 平均シェル厚みが0.1nm以上、10.0nm以下であるコア/シェル型半導体ナノ粒子とX線感応材料とを含むことを特徴とするナノ粒子標識薬。
- 前記X線感応材料がスカンジウム(Sc)、チタン(Ti)、バナジウム(V)、クロム(Cr)、鉄(Fe)、コバルト(Co)、ニッケル(Ni)、銅(Cu)、亜鉛(Zn)、ガリウム(Ga)、セレン(Se)、臭素(Br)、ルビジウム(Rb)、ストロンチウム(Sr)、イットリウム(Y)、ジルコニウム(Zr)、ニオブ(Nb)、モリブデン(Mo)、ルテニウム(Ru)、ロジウム(Rh)、パラジウム(Pd)、銀(Ag)、カドミウム(Cd)、イリジウム(Ir)、テルル(Te)、ヨウ素(I)、セシウム(Cs)、バリウム(Ba)、ランタン(La)、セリウム(Ce)、プラセオジム(Pr)、ネオジム(Nd)、プロメチウム(Pm)、サマリウム(Sm)、ユウロピウム(Eu)、ガドリニウム(Gd)、テルビウム(Tb)、ジスプロシウム(Dy)、ホルミウム(Ho)、エルビウム(Er)、ツリウム(Tm)、イッテルビウム(Yb)、ルテチウム(Lu)、ハフニウム(Hf)、タンタル(Ta)、タングステン(W)、オスミウム(Os)、イリジウム(Ir)、白金(Pt)、金(Au)から選択された少なくとも1種を含むことを特徴とする請求の範囲第1項に記載のナノ粒子標識薬。
- 前記コア/シェル型半導体ナノ粒子とX線感応材料とを結合するための物質を更に含むことを特徴とする請求の範囲第1項または第2項に記載のナノ粒子標識薬。
- 前記結合するための物質がSiO2であることを特徴とする請求の範囲第3項に記載のナノ粒子標識薬。
- 前記コア/シェル型半導体ナノ粒子のシェルにSiO2を含むことを特徴とする請求の範囲第1項~第4項のいずれか1項に記載のナノ粒子標識薬。
- 更に磁性粒子を含むことを特徴とする請求の範囲第1項~第5項のいずれか1項に記載のナノ粒子標識薬。
- 前記磁性粒子が超常磁性物質、常磁性物質または強磁性物質であることを特徴とする請求の範囲第6項に記載のナノ粒子標識薬。
- 前記超常磁性物質、常磁性物質または強磁性物質が金属酸化物であることを特徴とする請求の範囲第7項に記載のナノ粒子標識薬。
- 前記金属酸化物がコバルトの酸化物、ニッケルの酸化物、マンガンの酸化物及び鉄の酸化物からなる群より選択されることを特徴とする請求の範囲第8項に記載のナノ粒子標識薬。
- 前記鉄の酸化物がFe3O4またはγ-Fe2O3であることを特徴とする請求の範囲第9項に記載のナノ粒子標識薬。
- 前記常磁性物質がキレート化ガドリニウム複合体を母体とし、常磁性イオンをキレートの中に1種類以上を含むことを特徴とする請求の範囲第7項に記載のナノ粒子標識薬。
- 前記常磁性イオンがマンガン(Mn)、プラセオジム(Pr)、ネオジム(Nd)、サマリウム(Sm)、ユウロピウム(Eu)、テルビウム(Tb)、ジスプロシウム(Dy)、ホルミウム(Ho)、エルビウム(Er)、ツリウム(Tm)、イッテルビウム(Yb)及びルテチウム(Lu)の内の1種類以上を含むことを特徴とする請求の範囲第11項に記載のナノ粒子標識薬。
- 請求の範囲第1項~第5項のいずれか1項に記載のナノ粒子標識薬におけるコア/シェル型半導体ナノ粒子の蛍光を検出することができる第一モダリティー、及び請求の範囲第1項~第5項のいずれか1項に記載のナノ粒子標識薬におけるX線感応材料の吸収を検出することができる第二モダリティーを備えており、第一モダリティー及び第二モダリティーを同時に利用することができることを特徴とする高解像度インビボ画像を得るためのシステム。
- 前記第一モダリティーが光学イメージングを含み、前記第二モダリティーがX線イメージングを含むことを特徴とする請求の範囲第13項に記載の高解像度インビボ画像を得るためのシステム。
- 請求の範囲第6項~第12項のいずれか1項に記載のナノ粒子標識薬におけるコア/シェル型半導体ナノ粒子の蛍光を検出することができる第一モダリティー、請求の範囲第6項~第12項のいずれか1項に記載のナノ粒子標識薬におけるX線感応材料の吸収を検出することができる第二モダリティー、及び請求の範囲第6項~第12項のいずれか1項に記載のナノ粒子標識薬における磁性粒子の磁性を検出することができる第三モダリティーを備えており、第一モダリティー、第二モダリティー及び第三モダリティーが同時に利用することができることを特徴とする高解像度インビボ画像を得るためのシステム。
- 前記第一モダリティーが光学イメージングを含み、前記第二モダリティーがX線イメージングを含み、前記第三モダリティーが磁気共鳴イメージングを含むことを特徴とする請求の範囲第15項に記載の高解像度インビボ画像を得るためのシステム。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010520787A JP5644498B2 (ja) | 2008-07-17 | 2009-02-20 | ナノ粒子標識薬、及び該ナノ粒子標識薬を用いたシステム |
US13/003,481 US20110105889A1 (en) | 2008-07-17 | 2009-02-20 | Nanoparticle labeling and system using nanoparticle labeling |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-185857 | 2008-07-17 | ||
JP2008185857 | 2008-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010007803A1 true WO2010007803A1 (ja) | 2010-01-21 |
Family
ID=41550212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/053002 WO2010007803A1 (ja) | 2008-07-17 | 2009-02-20 | ナノ粒子標識薬、及び該ナノ粒子標識薬を用いたシステム |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110105889A1 (ja) |
JP (1) | JP5644498B2 (ja) |
WO (1) | WO2010007803A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102148068A (zh) * | 2010-02-04 | 2011-08-10 | 罗伯特.博世有限公司 | 导电材料 |
WO2011123613A1 (en) * | 2010-04-01 | 2011-10-06 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | A dual ct/mri nanoparticle contrast agent |
WO2013168622A1 (ja) * | 2012-05-08 | 2013-11-14 | 独立行政法人理化学研究所 | イメージングマーカーおよびその利用 |
JPWO2012153820A1 (ja) * | 2011-05-12 | 2014-07-31 | コニカミノルタ株式会社 | X線吸収蛍光ナノ粒子 |
JP2019094342A (ja) * | 2012-06-14 | 2019-06-20 | マイクロベンション インコーポレイテッドMicrovention, Inc. | ポリマー治療組成物を含むシステム |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993057B2 (en) * | 2011-10-22 | 2015-03-31 | Masoud Salavati-Niasari | Method for preparing silica-dysprosium oxide core-shell nanoparticles |
KR102275634B1 (ko) | 2012-10-15 | 2021-07-08 | 마이크로벤션, 인코포레이티드 | 폴리머 치료 조성물 |
CN105030820B (zh) * | 2015-04-30 | 2018-01-09 | 陈填烽 | 纳米硒作为x射线放疗增敏剂的应用 |
US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
CN109125744B (zh) * | 2018-08-24 | 2021-04-23 | 浙江大学 | 一种具有mri与ct双模态成像功能的钆掺杂氧化铪纳米颗粒的制备方法 |
CN112501432B (zh) * | 2020-11-16 | 2022-10-04 | 攀钢集团攀枝花钢铁研究院有限公司 | 一种含有高钛型钒钛磁铁矿的双相钒钛球团矿及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002530630A (ja) * | 1998-09-24 | 2002-09-17 | アドヴァンスト リサーチ アンド テクノロジー インスティチュート、インコーポレイティッド | 水溶性発光量子ドットおよびその生体分子コンジュゲート |
JP2003081882A (ja) * | 2001-09-10 | 2003-03-19 | Kyosei Seiyaku Kk | 硫酸バリウムx線造影剤 |
JP2003522149A (ja) * | 2000-02-08 | 2003-07-22 | ライスユニバーシティ | 治療法および診断法において使用される光学活性なナノ粒子 |
JP2003524147A (ja) * | 1998-09-18 | 2003-08-12 | マサチューセッツ インスティテュート オブ テクノロジー | 半導体ナノ結晶の生物学的用途 |
JP2003525914A (ja) * | 2000-03-06 | 2003-09-02 | マリンクロッド・インコーポレイテッド | 生理的機能の同時多重モデル測定 |
JP2003532898A (ja) * | 2000-05-05 | 2003-11-05 | バイエル アクチェンゲゼルシャフト | 生体標識としてのドープ処理されたナノ粒子 |
JP2003533363A (ja) * | 2000-05-17 | 2003-11-11 | ユニヴァーシティ オヴ フロリダ | 被覆されたナノ粒子 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8116845B2 (en) * | 2005-08-04 | 2012-02-14 | Dune Medical Devices Ltd. | Tissue-characterization probe with effective sensor-to-tissue contact |
US7235228B2 (en) * | 2003-04-15 | 2007-06-26 | The United States Of America As Represented By The Secretary Of The Navy | Fluorescent-magnetic nanoparticles with core-shell structure |
WO2005107818A2 (en) * | 2004-04-30 | 2005-11-17 | University Of Florida | Nanoparticles and their use for multifunctional bioimaging |
US8229200B2 (en) * | 2005-03-14 | 2012-07-24 | General Electric Company | Methods and systems for monitoring tumor burden |
US8014576B2 (en) * | 2005-11-23 | 2011-09-06 | The Medipattern Corporation | Method and system of computer-aided quantitative and qualitative analysis of medical images |
-
2009
- 2009-02-20 US US13/003,481 patent/US20110105889A1/en not_active Abandoned
- 2009-02-20 JP JP2010520787A patent/JP5644498B2/ja not_active Expired - Fee Related
- 2009-02-20 WO PCT/JP2009/053002 patent/WO2010007803A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003524147A (ja) * | 1998-09-18 | 2003-08-12 | マサチューセッツ インスティテュート オブ テクノロジー | 半導体ナノ結晶の生物学的用途 |
JP2002530630A (ja) * | 1998-09-24 | 2002-09-17 | アドヴァンスト リサーチ アンド テクノロジー インスティチュート、インコーポレイティッド | 水溶性発光量子ドットおよびその生体分子コンジュゲート |
JP2003522149A (ja) * | 2000-02-08 | 2003-07-22 | ライスユニバーシティ | 治療法および診断法において使用される光学活性なナノ粒子 |
JP2003525914A (ja) * | 2000-03-06 | 2003-09-02 | マリンクロッド・インコーポレイテッド | 生理的機能の同時多重モデル測定 |
JP2003532898A (ja) * | 2000-05-05 | 2003-11-05 | バイエル アクチェンゲゼルシャフト | 生体標識としてのドープ処理されたナノ粒子 |
JP2003533363A (ja) * | 2000-05-17 | 2003-11-11 | ユニヴァーシティ オヴ フロリダ | 被覆されたナノ粒子 |
JP2003081882A (ja) * | 2001-09-10 | 2003-03-19 | Kyosei Seiyaku Kk | 硫酸バリウムx線造影剤 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102148068A (zh) * | 2010-02-04 | 2011-08-10 | 罗伯特.博世有限公司 | 导电材料 |
WO2011123613A1 (en) * | 2010-04-01 | 2011-10-06 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | A dual ct/mri nanoparticle contrast agent |
JPWO2012153820A1 (ja) * | 2011-05-12 | 2014-07-31 | コニカミノルタ株式会社 | X線吸収蛍光ナノ粒子 |
WO2013168622A1 (ja) * | 2012-05-08 | 2013-11-14 | 独立行政法人理化学研究所 | イメージングマーカーおよびその利用 |
JP2013233267A (ja) * | 2012-05-08 | 2013-11-21 | Institute Of Physical & Chemical Research | イメージングマーカーおよびその利用 |
JP2019094342A (ja) * | 2012-06-14 | 2019-06-20 | マイクロベンション インコーポレイテッドMicrovention, Inc. | ポリマー治療組成物を含むシステム |
Also Published As
Publication number | Publication date |
---|---|
JP5644498B2 (ja) | 2014-12-24 |
US20110105889A1 (en) | 2011-05-05 |
JPWO2010007803A1 (ja) | 2012-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5644498B2 (ja) | ナノ粒子標識薬、及び該ナノ粒子標識薬を用いたシステム | |
Petoral Jr et al. | Synthesis and characterization of Tb3+-doped Gd2O3 nanocrystals: a bifunctional material with combined fluorescent labeling and MRI contrast agent properties | |
Das et al. | Gadolinium oxide ultranarrow nanorods as multimodal contrast agents for optical and magnetic resonance imaging | |
Soufi et al. | Eco-friendly and sustainable synthesis of biocompatible nanomaterials for diagnostic imaging: current challenges and future perspectives | |
Li et al. | Multifunctional upconversion-magnetic hybrid nanostructured materials: Synthesis and bioapplications | |
Li et al. | Hybrid lanthanide nanoparticles with paramagnetic shell coated on upconversion fluorescent nanocrystals | |
Xu et al. | Mixed lanthanide oxide nanoparticles as dual imaging agent in biomedicine | |
Lacroix et al. | New generation of magnetic and luminescent nanoparticles for in vivo real-time imaging | |
Ibarra-Ruiz et al. | Photoluminescent nanoplatforms in biomedical applications | |
Kharissova et al. | Ultrasmall particles and nanocomposites: state of the art | |
WO2010016289A1 (ja) | 量子ドットを含有する蛍光標識剤 | |
Taniguchi et al. | Synthesis of amphipathic YVO4: Eu3+ nanophosphors by oleate-modified nucleation/hydrothermal-growth process | |
Kattel et al. | Water-soluble ultrasmall Eu2O3 nanoparticles as a fluorescent imaging agent: In vitro and in vivo studies | |
Deng et al. | Effect of Eu doping concentration on fluorescence and magnetic resonance imaging properties of Gd2O3: Eu3+ nanoparticles used as dual-modal contrast agent | |
US20180177899A1 (en) | Hydrophilic particles, method for producing the same, and contrast agent utilizing same | |
Lee et al. | Hyaluronidase-sensitive SPIONs for MR/optical dual imaging nanoprobes | |
JPWO2009066548A1 (ja) | 半導体ナノ粒子、それを用いた蛍光標識物質及び分子・細胞イメージング法 | |
Chen et al. | Magnetic-fluorescent nanohybrids of carbon nanotubes coated with Eu, Gd Co-doped LaF3 as a multimodal imaging probe | |
Burbano et al. | Near-IR triggered photon upconversion: Imaging, detection, and therapy | |
Bazhukova et al. | Luminescent nanomaterials doped with rare earth ions and prospects for their biomedical applications (a review) | |
Khan et al. | Bifunctional nanomaterials: magnetism, luminescence and multimodal biomedical applications | |
Yadav et al. | Inorganic nanobiomaterials for medical imaging | |
Sun et al. | Fluorescence-magnetism functional EuS nanocrystals with controllable morphologies for dual bioimaging | |
Serge-Correales et al. | Size Control and Improved Aqueous Colloidal Stability of Surface-Functionalized ZnGa2O4: Cr3+ Bright Persistent Luminescent Nanoparticles | |
CN108743978B (zh) | 一种金@钆基配位聚合物纳米复合材料制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09797731 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010520787 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13003481 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09797731 Country of ref document: EP Kind code of ref document: A1 |